Liraglutide protects against atherosclerosis by attenuating endothelial-monocyte adhesion via `LOX-1/NF-κB` pathway.

Atherosclerosis, a chronic inflammatory disease, remains a leading cause of cardiovascular morbidity and mortality. It is often exacerbated by conditions like hypercholesterolemia and diabetes. Current treatments target lipid levels but often fall short in fully addressing the complex inflammatory processes, particularly the early stages involving endothelial dysfunction and monocyte adhesion. The LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1) receptor plays a critical role in mediating oxidized LDL uptake and activating pro-inflammatory pathways like NF-κB, contributing significantly to plaque formation. Investigating agents like GLP-1 agonists, known for their pleiotropic effects beyond glycemic control, offers a promising avenue to target these specific inflammatory mechanisms.

The provided research record is a correction notice, and the original study's abstract details are not available. Therefore, specific methodological parameters such as model species, sample size, precise liraglutide dosage, administration route, treatment duration, or specific primary endpoints cannot be detailed. The study investigated the protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis, focusing on its impact on endothelial-monocyte adhesion and the underlying LOX-1/NF-κB signaling pathway. Without the full abstract, details on specific assays (e.g., ELISA, qPCR, flow cytometry) or control arms are also not available.

The original study demonstrated that liraglutide exerts protective effects against hypercholesterolemia-associated atherosclerosis. This beneficial action was mechanistically linked to the down-regulation of the LOX-1/NF-κB signaling pathway. By modulating this pathway, liraglutide likely reduces the inflammatory cascade initiated by oxidized low-density lipoprotein (ox-LDL) and subsequently inhibits the recruitment of monocytes to the arterial wall. While specific quantitative data, such as percentage reductions, p-values, or fold-changes, are not provided in this record, the finding points to a significant anti-atherosclerotic effect mediated through a distinct anti-inflammatory mechanism. > Specifically, liraglutide was found to attenuate endothelial-monocyte adhesion, a critical early step in atherosclerotic plaque development.